Diabeta, Glynase (glyburide) dosing, indications, interactions, adverse effects, and more

Sections

Sections glyburide
Dosing & Uses
Interactions
Adverse Effects
Warnings
Pregnancy
Pharmacology
Images
Patient Handout
Formulary

Dosing & Uses

AdultPediatricGeriatric

Dosage Forms & Strengths

tablet

1.25mg
2.5mg
5mg

tablet, micronized

1.5mg
3mg
5mg
6mg

Type 2 Diabetes Mellitus

Regular tablets

Initial: 2.5-5 mg PO qDay
Maintenance: 1.25-20 mg PO qDay or q12hr
Not to exceed 20 mg/day
Consider administering q12hr for doses >10 mg/day

Micronized tablets

Initial: 1.5-3 mg PO qDay
Maintenance: 0.75-12 mg PO qDay
Not to exceed 12 mg/day
Patients at risk for hypoglycemia: 0.75 mg PO qDay initially

Transferring from insulin therapy to glyburide

Current insulin dose <20 units: Discontinue insulin and initiate glyburide dose at 2.5-5 mg/day (regular) or 1.5-3 mg/day (micronized)
Current insulin dose 20-40 units: Discontinue insulin and initiate glyburide dose at 5 mg/day (regular) or 3 mg/day (micronized)
Current insulin dose >40 units: Decrease insulin dose by 50% and initiate glyburide dose at 5 mg/day (regular) or 3 mg/day (micronized); increase glyburide dose by 1.25-2.5 mg (regular) or 0.75-1.5 mg/day (micronized); decrease insulin dose gradually, based on patient’s response as glyburide dose increased

Dosage Modifications

Renal impairment: If CrCl <50 mL/min; caution advised

Hepatic impairment: Use conservative initial and maintenance doses; avoid use in severe liver disease

Orphan Designations

Acute spinal cord injury

Acute subarachnoid hemorrhage

Acute ischemic stroke

Sponsor

Remedy Pharmaceuticals, Inc; 122 W. 27th Street 10th Floor; New York, NY 10001

Safety and efficacy not established

Type 2 Diabetes

Initial: 1.25 mg/day if nonmicronized tablets or 0.75 mg/day of micronized tablets

Depending on glucose response, may increase dose by no more than 1.25-2.5 mg (regular) or 0.75-1.5 mg (micronized) every week

May administer maintenance dose of 1.25-20 mg/day (regular) or 0.75-12 mg/day (micronized); for better satisfactory response may divide dose q12hr for patients taking >10 mg/day (regular) or >6 mg/day (micronized)

Dosing considerations

Because the elderly are susceptible to the hypoglycemic effects of glucose-lowering drugs, the question of how tightly glucose levels should be controlled is controversial

Recognizing hypoglycemia in the elderly may be challenging

Monitoring other parameters associated with cardiovascular disease, such as blood pressure and cholesterol, may be more important than normalized glycemic control

Initial and maintenance dosing should be conservative

Use caution in patients with renal insufficiency

Interaction Checker

Enter a drug name and glyburide

No Results

No Interactions Found

Interactions Found

Contraindicated

Serious - Use Alternative

Significant - Monitor Closely

Minor

All Interactions Sort By:

Frequency Not Defined

Angioedema

Urticaria

Rash

Morbilliform eruptions

Pruritus

Photosensitivity reaction

Heartburn

Vasculitis

Disulfiram-like reaction

Hyponatremia

Nocturia

Agranulocytosis

Hemolytic anemia

Pancytopenia

Thrombocytopenia

Porphyria cutanea tarda

Arthralgia

Paresthesia

Myalgia

Blurred vision

Diuretic effect (minor)

Hypoglycemia

Nausea/vomiting

Cholestatic jaundice and hepatitis, which occur only rarely, may progress to liver failure

Weight gain

Bullous reactions, erythema multiforme, and exfoliative dermatitis

Contraindications

Hypersensitivity; sulfa allergy

Type 1 diabetes

Diabetic ketoacidosis with or without coma

Coadministration with bosentan; increased risk of hepatotoxicity

Cautions

Risk of hypoglycemia increases when caloric intake is deficient, when more than one glucose-lowering agent used, when ethanol is ingested, or after severe or prolonged exercise; hypoglycemia is also morelikely to occur in elederly patients, malnourished or debilitated patients, and in patients with adrenal and/or pituitary insufficiency, and patients with severe hepatic and hepatic impairment

Concerns for cross-reactivity between agents containing sulfonamide products has been reported for patients with prior allergic reactions to any compound with the sulfonamide structure SO2NH2; an expanding understanding of allergic mechanisms suggest that cross-reactivity between antibiotic sulfonamides and nonantibiotic sulfonamides may not occur or at the very least the potential is extremely low

Caution in pregnancy/lactation

Administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin; latest studies, however, do not support association

Hemolytic anemia may occur with glucose 6-phosphate dehydrogenase (G6PD) deficiency when treated with sulfonylurea agents; use caution and consider a nonsulfonylurea alternative in patients with G6PD deficiency

There are no clinical studies establishing conclusive evidence of macrovascular risk reduction with anti-diabetic drugs

Use of glyburide not recommended in chronic kidney disease; metabolism and excretion of glyburide may be slowed in aptients with renal impairment and its active metabolites, causing accumulation in advanced renal insufficiency; prolonged hypoglycemia could occur

It may be necessary to discontinue therapy and administer insulin if patient exposed to stress

Micronized tablet formulation is not bioequivalent to conventional glyburide tablets; when transferring patient to a different glyburide formulation, retitrate the dose

Beta cell destruction may occur following prolonged use of therapy, which may result in loss of treatment efficacy in type 2 diabetes mellitus; discontinue therapy if loss of efficacy occurs in patients who were previously responding to treatment and no contributing factors can be identified

All sulfonylureas are capable of producing severe hypoglycemia

Pregnancy & Lactation

Pregnancy category: C

Lactation: Not known if crosses into breast milk; avoid use in nursing women

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Mechanism of Action

Initial effect is to increase beta-cell insulin secretion

May also decrease rate of hepatic glucose production and increase insulin receptor sensitivity

Absorption

Bioavailability: Variable, depending on oral dosage form

Onset: 15-60 min after a single dose (increase in serum insulin levels)

Duration: <24 hr

Vd: 9-10 L

Peak serum time: 2-4 hr (adults)

Distribution

Protein bound: 99%

Metabolism

Metabolized extensively in the liver to less-active metabolites

Metabolites: 4-trans-hydroxyglyburide, 3-cis-hydroxyglyburide (active)

Elimination

Half-life: 10 hr (DiaBeta); 4 hr (Glynase, PresTab)

Excretion: Urine (50%), feces (50%)

Images

Patient Handout

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Create Your List of Plans

Adding plans allows you to:

View the formulary and any restrictions for each plan.
Manage and view all your plans together – even plans in different states.
Compare formulary status to other drugs in the same class.
Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

View explanations for tiers and restrictions

Tier	Description
1	This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2	This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC	NOT COVERED – Drugs that are not covered by the plan.

Code	Definition
PA	Prior Authorization Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL	Quantity Limits Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST	Step Therapy Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR	Other Restrictions Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.

Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.

[CLOSE WINDOW]

Sections glyburide
Dosing & Uses
Interactions
Adverse Effects
Warnings
Pregnancy
Pharmacology
Images
Patient Handout
Formulary

glyburide (Rx)